201 related articles for article (PubMed ID: 23792071)
1. The circulating level of MMP-9 and its ratio to TIMP-1 as a predictor of severity in patients with community-acquired pneumonia.
Chiang TY; Yu YL; Lin CW; Tsao SM; Yang SF; Yeh CB
Clin Chim Acta; 2013 Sep; 424():261-6. PubMed ID: 23792071
[TBL] [Abstract][Full Text] [Related]
2. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia.
Chiang TY; Shyu LY; Tsao TC; Chien MH; Tsao SM; Lee YT; Yang SF
Clin Chem Lab Med; 2011 Nov; 50(3):449-54. PubMed ID: 22107133
[TBL] [Abstract][Full Text] [Related]
3. Relation of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in peripheral circulating CD14+ monocytes to progression of coronary artery disease.
Brunner S; Kim JO; Methe H
Am J Cardiol; 2010 Feb; 105(4):429-34. PubMed ID: 20152234
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors.
Tedeschi A; Asero R; Lorini M; Marzano AV; Cugno M
Clin Exp Allergy; 2010 Jun; 40(6):875-81. PubMed ID: 20214668
[TBL] [Abstract][Full Text] [Related]
5. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
6. Excessive matrix metalloproteinase-9 in the plasma of community-acquired pneumonia.
Yang SF; Chu SC; Chiang IC; Kuo WF; Chiou HL; Chou FP; Kuo WH; Hsieh YS
Clin Chim Acta; 2005 Feb; 352(1-2):209-15. PubMed ID: 15653116
[TBL] [Abstract][Full Text] [Related]
7. A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury.
Jacob-Ferreira AL; Passos CJ; Gerlach RF; Barbosa F; Tanus-Santos JE
Sci Total Environ; 2010 Sep; 408(19):4085-92. PubMed ID: 20554312
[TBL] [Abstract][Full Text] [Related]
8. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
9. Host single nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection.
Hung KH; Hung HW; Yang HB; Lu CC; Wu JJ; Sheu BS
Helicobacter; 2009 Dec; 14(6):580-7. PubMed ID: 19889076
[TBL] [Abstract][Full Text] [Related]
10. Serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in patients with tick-borne encephalitis.
Palus M; Zampachová E; Elsterová J; Růžek D
J Infect; 2014 Feb; 68(2):165-9. PubMed ID: 24091083
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
12. Role of polymorphisms in MMP-9 and TIMP-1 as biomarkers for susceptibility to systemic lupus erythematosus patients.
Vira H; Pradhan V; Umare V; Chaudhary A; Rajadhyksha A; Nadkar M; Ghosh K; Nadkarni A
Biomark Med; 2019 Jan; 13(1):33-43. PubMed ID: 30561224
[TBL] [Abstract][Full Text] [Related]
13. Plasma d-dimer levels increase with the severity of community acquired pneumonia.
Güneysel O; Pirmit S; Karakurt S
Tuberk Toraks; 2004; 52(4):341-7. PubMed ID: 15558356
[TBL] [Abstract][Full Text] [Related]
14. Specific matrix metalloproteinase 9 (MMP-9) haplotype affect the circulating MMP-9 levels in women with migraine.
Martins-Oliveira A; Gonçalves FM; Speciali JG; Fontana V; Izidoro-Toledo TC; Belo VA; Dach F; Tanus-Santos JE
J Neuroimmunol; 2012 Nov; 252(1-2):89-94. PubMed ID: 22907074
[TBL] [Abstract][Full Text] [Related]
15. Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels.
Marson BP; Lacchini R; Belo V; Mattos SG; da Costa BP; Poli-de-Figueiredo CE; Tanus-Santos JE
Clin Chim Acta; 2012 Dec; 414():46-51. PubMed ID: 23010359
[TBL] [Abstract][Full Text] [Related]
16. Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia.
Yeh YH; Chang JL; Hsiao PC; Tsao SM; Lin CH; Kao SJ; Chou MC; Yang SF; Chien MH
J Clin Lab Anal; 2013 Jul; 27(4):253-60. PubMed ID: 23852780
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
[TBL] [Abstract][Full Text] [Related]
18. Pro-MMP-9/TIMP-1 ratio correlates poorly with a direct assessment of MMP-9 activity.
Tarr GP; Williams MJ; Phillips LV; van Rij AM; Jones GT
Clin Biochem; 2011 Dec; 44(17-18):1480-2. PubMed ID: 22020222
[TBL] [Abstract][Full Text] [Related]
19. MMP-9 1562C>T Gene Polymorphism and Efficacy of Glucocorticoid Therapy in Idiopathic Pulmonary Fibrosis Patients.
Zhang HT; Fang SC; Wang CY; Wang W; Wu J; Wang C; Xu B; Zhang YM
Genet Test Mol Biomarkers; 2015 Nov; 19(11):591-7. PubMed ID: 26401883
[TBL] [Abstract][Full Text] [Related]
20. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.
Inokubo Y; Hanada H; Ishizaka H; Fukushi T; Kamada T; Okumura K
Am Heart J; 2001 Feb; 141(2):211-7. PubMed ID: 11174334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
